BRIEF-UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients

United Community Banks, Inc.

United Community Banks, Inc.

UCB

0.00

June 17 (Reuters) - Ucb SA UCB.BR:

  • ANNOUNCES DATA SHOWING POSITIVE IMPACT OF KYGEVVI IN TK2D PATIENTS

  • KYGEVVI IS FIRST AND ONLY APPROVED TREATMENT FOR EARLY-ONSET TK2D

  • KYGEVVI APPROVED BY FDA IN NOV 2025 AND EMA IN MAR 2026

  • KYGEVVI REDUCED RISK OF DEATH BY 92%-94% IN EARLY-ONSET TK2D PATIENTS

Source text: ID:nPn1mJkKda

Further company coverage: UCB.BR


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.